Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 29, 2022

Primary Completion Date

November 3, 2022

Study Completion Date

January 15, 2023

Conditions

Glucocorticoids ToxicityCOVID-19Infectious DiseaseVirus Diseases

Interventions

DRUG

101-PGC-005

Bolus Injection containing 30mg of 101-PGC-005 will administered intravenously once daily for 3 consecutive days

Trial Locations (1)

ICBio Clinical Research Pvt. Ltd., Bangalore